UNSPSC 51191518: Methyclothiazide

This classification denotes a thiazide diuretic with the molecular formula C9H11Cl2N3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L3H46UAC61, chemically known as 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide but generally known as methyclothiazide, which bears US NIH Compound Identifier 4121. European Medicines Agency schedules Methyclothiazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08861MIG.

UNSPSC 51191518 Methyclothiazide, a Commodity code, covers pharmaceutical products that state and local governments procure for healthcare delivery and water treatment operations. The recent opportunities under this code show a marked disconnect between the code's nominal scope and actual purchasing activity: the City of Meriden's solicitation B027-15 (IFB, due July 29, 2026) seeks sodium bisulfite, a water-treatment chemical unrelated to the methyclothiazide classification, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802 (due March 26, 2026) targets generic multi-source pharmaceuticals and OTC products distributed through state and local government facilities. The MMCAP opportunity represents the more relevant activity to the code's pharmaceutical scope and illustrates the kinds of buyers active here: state purchasing offices administering cooperative agreements that serve multiple jurisdictions and their subordinate facilities. The Meriden chemical supply solicitation, while tagged under this code, reflects catalog misclassification rather than pharmaceutical procurement.

Geographic activity centers on the Upper Midwest and Northeast, with Minnesota's MMCAP serving participating states including Oregon and Connecticut (through the Meriden municipality). The MMCAP procurement is the standout representative opportunity: a multi-award RFP administered by the Minnesota Department of Administration's Office of State Procurement requiring vendors to supply pharmaceuticals through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with pricing weighted 75 percent on competitiveness, 10 percent on fixed pricing for contract term, and the remainder on administrative compliance and EDI capability. Vendors must certify cGMP and DSCSA compliance, maintain relationships with at least two of the three wholesalers, and carry $5 million in commercial general liability and $2 million each in network security and professional liability coverage. The contract term runs two years for new responders with optional extensions, and a 3 percent administrative fee applies to all purchases.